Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Address correspondence to: Bettina Winzeler, University Hospital Basel, Department of Endocrinology, Diabetology und Metabolism, Petersgraben 4, 4031 Basel, Switzerland
In terms of the primary outcome of reduction in A1C from baseline, although the 3-mg oral semaglutide group did not demonstrate superiority to sitagliptin 100 mg at 26 weeks, the 7-mg and 14-mg dosage groups did demonstrate statistically significant reductions in A1C from baseline when compared with sitagliptin
ONeil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, et al
Orders are being processed and dispatched as normal, however can be subject to routine customs checks, which can cause delays
US$ 24.62
US$ 22.22
US$ 22.31
